Adma Biologics Inc (NASDAQ: ADMA) Plunges -0.23% And Its 5.09% Stock Volatility Is Bewildering

Adma Biologics Inc (NASDAQ:ADMA) does about 2.76M shares in volume on a normal day but saw 5064359 shares change hands in Monday’s trading. The company now has a market cap of 2.04B USD. Its current market price is $8.79, marking a decrease of -0.23% compared to the previous close of $8.81. The 52 week high reached by this stock is $9.02 whilst the lowest price level in 52 weeks is $3.06.

Adma Biologics Inc (ADMA) has a 20-day trading average at $6.77 and the current price is -2.55% off the 52-week high compared with 187.25% distance from its 52-week low. The 50-day simple moving average of the closing price is $6.44 and its 200-day simple moving average is $4.74. If we look at the stock’s price movements over the week, volatility stands at 5.09%, which decreases to 3.90% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 86.52 to suggest the stock is overbought.

The consensus objective for the share price is $10.50, suggesting that the stock has a potential upside of 16.29% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on July 19, 2023 when Raymond James resumed the stock to “Strong Buy” and issued a price target of $5. Raymond James upgraded its price target at $5.

Adma Biologics Inc (ADMA) stock is up 27.21% over the week and 46.01% over the past month. Its price is 94.47% year-to-date and 121.97% over the past year.

The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -0.03 above consensus estimates by 0.01. The company’s next earnings report forecasts estimating quarterly EPS at 0.05 and 0.35 for whole year. Expected sales for next quarter are $86.41M, which analysts say will come at $337.03M for the current fiscal year and next year at $414.48M. In addition, estimates put the company’s current quarterly revenue at an average of $81.88M.

To reach the target analysts have set, the stock logically needs to grow 16.29 percent from here.

The company has a return on investment of -1.24% and return on equity of -2.43%. The forward price to earnings ratio is 16.28. The beta has a value of 0.44. Price to book ratio is 13.25 and price to sales ratio is 7.19.